Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Desensitization Protocol for Deceased Donor List

This study has been completed.
Information provided by (Responsible Party):
Junichiro Sageshima, University of Miami Identifier:
First received: July 12, 2012
Last updated: October 17, 2014
Last verified: October 2014

Purpose of the study:

The specific aims of this study are to evaluate overall efficacy and safety of the pre-transplant IVIG treatment in our transplant center since 2007 and to identify factors affecting treatment outcomes in order to improve patient selection and treatment protocols for future patients.

Transplant; Failure, Kidney

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Desensitization Protocol for Deceased Donor List

Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Anti HLA antibody level [ Time Frame: after IVIG infusion ]

Secondary Outcome Measures:
  • Number of patients transplanted [ Time Frame: at the end of study ]

Enrollment: 180
Study Start Date: June 2012
Study Completion Date: June 2014
Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Detailed Description:


Intravenous immunoglobulin (IVIG) infusion is one of several novel approaches to decrease antibody levels for highly sensitized kidney transplant candidates [1, 2]. This approach can potentially give a chance of kidney transplantation to end-stage renal failure patients who could never receive transplantation because of high levels of antibodies and persistent positive crossmatches to all potential kidney donors. Many transplant centers have used this strategy in order to increase transplant rates of highly sensitized patients with various levels of anti-HLA antibodies. However, the responses to the treatment seem to be different in each patient and factors affecting treatment outcome have yet to be determined.


Ages Eligible for Study:   7 Years to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Approximately 100 subjects are expected to participate from 2007 to current, and another 100 subjects are expected to participate during the next 12-month period.

Inclusion Criteria:

  • Recent (< 3 months) high levels of anti-HLA antibodies (at least one cPRA ≥ 40%).
  • Waiting time greater than 1 year for blood type AB, 2 years for blood types A, B, or O.

Exclusion Criteria:

  • Female subject is pregnant or lactating.
  • Subject has an uncontrolled concomitant infection or any other unstable medical condition (e.g., uncontrolled cardiovascular disease) that could interfere with the study objectives.
  • Subject has an uncontrolled active hepatitis B, hepatitis C, or HIV infection.
  • Subject has a current malignancy or a recent history of any malignancy that is deemed to be contraindicated to kidney transplantation.
  • Subject has a psychiatric illness that, in the judgment of caring physicians, may interfere with study participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01642225

United States, Florida
University of Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Principal Investigator: Junichiro Sageshima, M.D. University of Miami
  More Information

Responsible Party: Junichiro Sageshima, Associate Professor of Clinical, University of Miami Identifier: NCT01642225     History of Changes
Other Study ID Numbers: 20120052
Study First Received: July 12, 2012
Last Updated: October 17, 2014

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases processed this record on April 28, 2017